The safety of biological medicines for Rheumatoid Arthritis

Advances in Experimental Medicine and Biology

Volumn 822, Issue , 2015, Pages 209-210

  Papadopoulos, Ioannis ^a   Demetzos, Costas ^a   Markantoni Kyroudi, Sofia ^a   Souliotis, Kyriakos ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PELOPONNESE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; ANTIRHEUMATIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ALGORITHM; ARTICLE; BIOTECHNOLOGY; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; HEALTH CARE SYSTEM; HUMAN; HYPERPLASIA; INFECTION; INJECTION SITE INFLAMMATION; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRESCRIPTION; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; ADVERSE EFFECTS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; INFLAMMATION; INJECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; GASTROINTESTINAL DISEASES; HUMANS; HYPERPLASIA; INFECTION; INFLAMMATION; INJECTIONS; MUSCULOSKELETAL DISEASES;

EID: 84912033544     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-08927-0_26     Document Type: Article

References (3)

1. Takeuchi T (2011) Revolutionary change in Rheumatoid arthritis management with biological therapy. Keio J Med 60:3
2. Pirmohamed M (2002) Adverse drug reactions-back to future. Br J Clin Pharmacol 55:486-492
3. Furneri G (2012) Systemic literature review on economic implications and pharmacoeconomics issues of rheumatoid arthritis. Clin Exp Rheumatol 30:73